Nkarta, Inc. (NASDAQ:NKTX) Shares Acquired by Barclays PLC

Barclays PLC increased its holdings in shares of Nkarta, Inc. (NASDAQ:NKTX) by 161.4% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 232,566 shares of the company’s stock after purchasing an additional 143,608 shares during the quarter. Barclays PLC owned 0.33% of Nkarta worth $1,051,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of NKTX. Wasatch Advisors LP boosted its position in shares of Nkarta by 31.7% in the third quarter. Wasatch Advisors LP now owns 1,834,680 shares of the company’s stock worth $8,293,000 after buying an additional 442,125 shares during the period. Geode Capital Management LLC lifted its position in Nkarta by 3.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,171,026 shares of the company’s stock worth $5,294,000 after acquiring an additional 33,927 shares in the last quarter. State Street Corp boosted its holdings in Nkarta by 1.4% in the 3rd quarter. State Street Corp now owns 1,098,062 shares of the company’s stock worth $4,963,000 after acquiring an additional 15,569 shares during the period. Renaissance Technologies LLC grew its position in Nkarta by 12.0% in the second quarter. Renaissance Technologies LLC now owns 912,872 shares of the company’s stock valued at $5,395,000 after acquiring an additional 98,000 shares in the last quarter. Finally, Marshall Wace LLP raised its stake in shares of Nkarta by 136.7% during the second quarter. Marshall Wace LLP now owns 439,973 shares of the company’s stock valued at $2,600,000 after purchasing an additional 254,104 shares during the period. Institutional investors and hedge funds own 80.54% of the company’s stock.

Nkarta Stock Performance

Shares of Nkarta stock opened at $2.21 on Wednesday. Nkarta, Inc. has a 1 year low of $2.08 and a 1 year high of $16.24. The firm’s 50-day simple moving average is $2.58 and its 200-day simple moving average is $4.23. The firm has a market cap of $155.96 million, a PE ratio of -1.18 and a beta of 0.85.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on NKTX. Needham & Company LLC decreased their target price on shares of Nkarta from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, November 8th. Rodman & Renshaw initiated coverage on shares of Nkarta in a research report on Wednesday, October 9th. They issued a “buy” rating and a $14.00 price objective for the company. HC Wainwright dropped their target price on Nkarta from $22.00 to $18.00 and set a “buy” rating on the stock in a research report on Monday, November 11th. Mizuho cut their price target on Nkarta from $20.00 to $16.00 and set an “outperform” rating on the stock in a research note on Thursday, November 21st. Finally, RODMAN&RENSHAW upgraded Nkarta to a “strong-buy” rating in a research note on Wednesday, October 9th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Nkarta presently has a consensus rating of “Buy” and a consensus price target of $15.00.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.